GDNF - A potential target to treat addiction

Pharmacology and Therapeutics

Volumn 122, Issue 1, 2009, Pages 9-18

  Carnicella, Sebastien ^a   Ron, Dorit ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction; Alcohol; GDNF; Growth factor; Opioids; Psychostimulants

Indexed keywords

18 METHOXYCORONARIDINE; ALCOHOL; CABERGOLINE; CALCITRIOL; COCAINE; COGANE; DIPEPTIDE; DRUGS USED IN THE TREATMENT OF ADDICTION; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; LADOSTIGIL; LEUCYLISOLEUCINE; MESSENGER RNA; METHAMPHETAMINE; MORPHINE; NALOXONE; NICOTINE; OPIATE; PROTEIN RET; PSYCHOSTIMULANT AGENT; PYM 50028; RASAGILINE; SMILAGENIN; TACROLIMUS; UNCLASSIFIED DRUG; XIB 4035;

ALCOHOL ABUSE; ANIMAL BEHAVIOR; DOPAMINERGIC NERVE CELL; DRUG ABUSE; DRUG DEPENDENCE; DRUG RESEARCH; HUMAN; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; DOPAMINE; DRUG DELIVERY SYSTEMS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NEURONS; SIGNAL TRANSDUCTION; SUBSTANCE-RELATED DISORDERS;

EID: 63049083676     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.12.001     Document Type: Review

References (151)

1. Ai Y., Markesbery W., Zhang Z., Grondin R., Elseberry D., Gerhardt G.A., et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 461 (2003) 250-261
2. Airaksinen M.S., and Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3 (2002) 383-394
3. Airavaara M., Mijatovic J., Vihavainen T., Piepponen T.P., Saarma M., and Ahtee L. In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered. Synapse 59 (2006) 321-329
4. Airavaara M., Planken A., Gaddnas H., Piepponen T.P., Saarma M., and Ahtee L. Increased extracellular dopamine concentrations and FosB/DeltaFosB expression in striatal brain areas of heterozygous GDNF knockout mice. Eur J Neurosci 20 (2004) 2336-2344
5. Airavaara M., Tuomainen H., Piepponen T.P., Saarma M., and Ahtee L. Effects of repeated morphine on locomotion, place preference and dopamine in heterozygous glial cell line-derived neurotrophic factor knockout mice. Genes Brain Behav 6 (2007) 287-298
6. Albeck D.S., Hoffer B.J., Quissell D., Sanders L.A., Zerbe G., and Granholm A.C. A non-invasive transport system for GDNF across the blood-brain barrier. Neuroreport 8 (1997) 2293-2298
7. Alper K.R., Lotsof H.S., and Kaplan C.D. The ibogaine medical subculture. J Ethnopharmacol 115 (2008) 9-24
8. Azzouz M., Ralph S., Wong L.F., Day D., Askham Z., Barber R.D., et al. Neuroprotection in a rat Parkinson model by GDNF gene therapy using EIAV vector. Neuroreport 15 (2004) 985-990
9. Barroso-Chinea P., Cruz-Muros I., Aymerich M.S., Rodriguez-Diaz M., Afonso-Oramas D., Lanciego J.L., et al. Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. Eur J Neurosci 21 (2005) 1815-1827
10. Baumann M.H., Rothman R.B., Pablo J.P., and Mash D.C. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats. J Pharmacol Exp Ther 297 (2001) 531-539
11. Beck K.D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R.A., et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy- induced degeneration in the adult brain. Nature 373 (1995) 339-341
12. Beitner-Johnson D., and Nestler E.J. Morphine and cocaine exert common chronic actions on tyrosine hydroxylase in dopaminergic brain reward regions. J Neurochem 57 (1991) 344-347
13. Belin D., Deroche-Gamonet V., and Jaber M. Cocaine-induced sensitization is associated with altered dynamics of transcriptional responses of the dopamine transporter, tyrosine hydroxylase, and dopamine D2 receptors in C57Bl/6J mice. Psychopharmacology (Berl) 193 (2007) 567-578
14. Berhow M.T., Russell D.S., Terwilliger R.Z., Beinter-Johnson D., Self D.W., Lindsay R.M., and Nestler E.J. Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbic dopamine system. Neuroscience 68 (1995) 969-979
15. Boado R.J., Zhang Y., Zhang Y., Wang Y., and Pardridge W.M. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. Biotechnol Bioeng 100 (2008) 387-396
16. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 16 Suppl 1 (2003) S13-19
17. Bourque M.J., and Trudeau L.E. GDNF enhances the synaptic efficacy of dopaminergic neurons in culture. Eur J Neurosci 12 (2000) 3172-3180
18. Burazin T.C., and Gundlach A.L. Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum. Brain Res Mol Brain Res 73 (1999) 151-171
19. Carnicella, S., Ahmadiantehrani, S., He, D.-Y., Nielsen, C.K., Bartlett, S.E., Patricia, H., Janak, P.H., & Ron, D., (2009a). The FDA-approved drug cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor. Biological Psychiatry in revision.
20. Carnicella, S., Amamoto, R. & Ron, D., (2009b). Excessive alcohol consumption is blocked by GDNF. Alcohol in revision.
21. Carnicella S., Kharazia V., Jeanblanc J., Janak P.H., and Ron D. GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci U S A 105 (2008) 8114-8119
22. Cass W.A. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J Neurosci 16 (1996) 8132-8139
23. Cen X., Nitta A., Ohya S., Zhao Y., Ozawa N., Mouri A., et al. An analog of a dipeptide-like structure of FK506 increases glial cell line-derived neurotrophic factor expression through cAMP response element-binding protein activated by heat shock protein 90/Akt signaling pathway. J Neurosci 26 (2006) 3335-3344
24. Chao C.C., Ma Y.L., Chu K.Y., and Lee E.H. Integrin alphav and NCAM mediate the effects of GDNF on DA neuron survival, outgrowth, DA turnover and motor activity in rats. Neurobiol Aging 24 (2003) 105-116
25. Choi-Lundberg D.L., and Bohn M.C. Ontogeny and distribution of glial cell line-derived neurotrophic factor (GDNF) mRNA in rat. Brain Res Dev Brain Res 85 (1995) 80-88
26. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275 (1997) 838-841
27. Colao A., Di Sarno A., Guerra E., De Leo M., Mentone A., and Lombardi G. Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab 2 (2006) 200-210
28. Consales C., Volpicelli F., Greco D., Leone L., Colucci-D'Amato L., Perrone-Capano C., et al. GDNF signaling in embryonic midbrain neurons in vitro. Brain Res 1159 (2007) 28-39
29. Coulpier M., Anders J., and Ibanez C.F. Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival. J Biol Chem 277 (2002) 1991-1999
30. Delgrange E. Cabergoline and mitral regurgitation. N Engl J Med 354 (2006) 420 author reply 420
31. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85 (1998) 5274-5278
32. Durbec P., Marcos-Gutierrez C.V., Kilkenny C., Grigoriou M., Wartiowaara K., Suvanto P., et al. GDNF signalling through the Ret receptor tyrosine kinase. Nature 381 (1996) 789-793
33. Eketjall S., Fainzilber M., Murray-Rust J., and Ibanez C.F. Distinct structural elements in GDNF mediate binding to GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex. EMBO J 18 (1999) 5901-5910
34. Encinas M., Tansey M.G., Tsui-Pierchala B.A., Comella J.X., Milbrandt J., and Johnson Jr. E.M. c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J Neurosci 21 (2001) 1464-1472
35. Eslamboli A., Cummings R.M., Ridley R.M., Baker H.F., Muzyczka N., Burger C., et al. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol 184 (2003) 536-548
36. Eslamboli A., Georgievska B., Ridley R.M., Baker H.F., Muzyczka N., Burger C., et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25 (2005) 769-777
37. Esposito C.L., D'Alessio A., de Franciscis V., and Cerchia L. A cross-talk between TrkB and Ret tyrosine kinases receptors mediates neuroblastoma cells differentiation. PLoS One 3 (2008) e1643
38. Georgievska B., Kirik D., Rosenblad C., Lundberg C., and Bjorklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13 (2002) 75-82
39. Georgievska B., Kirik D., and Bjorklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci 24 (2004) 6437-6445
40. Gerlai R., McNamara A., Choi-Lundberg D.L., Armanini M., Ross J., Powell-Braxton L., et al. Impaired water maze learning performance without altered dopaminergic function in mice heterozygous for the GDNF mutation. Eur J Neurosci 14 (2001) 1153-1163
41. Glazner G.W., Mu X., and Springer J.E. Localization of glial cell line-derived neurotrophic factor receptor alpha and c-ret mRNA in rat central nervous system. J Comp Neurol 391 (1998) 42-49
42. Glick S.D., Kuehne M.E., Maisonneuve I.M., Bandarage U.K., and Molinari H.H. 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res 719 (1996) 29-35
43. Glick S.D., Pearl S.M., Cai J., and Maisonneuve I.M. Ibogaine-like effects of noribogaine in rats. Brain Res 713 (1996) 294-297
44. Glick S.D., and Maisonneuve I.M. Development of novel medications for drug addiction. The legacy of an African shrub. Ann N Y Acad Sci 909 (2000) 88-103
45. Golden J.P., Baloh R.H., Kotzbauer P.T., Lampe P.A., Osborne P.A., Milbrandt J., et al. Expression of neurturin, GDNF, and their receptors in the adult mouse CNS. J Comp Neurol 398 (1998) 139-150
46. Golden J.P., DeMaro J.A., Osborne P.A., Milbrandt J., and Johnson Jr. E.M. Expression of neurturin, GDNF, and GDNF family-receptor mRNA in the developing and mature mouse. Exp Neurol 158 (1999) 504-528
47. Graham D.L., Edwards S., Bachtell R.K., DiLeone R.J., Rios M., and Self D.W. Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci 10 (2007) 1029-1037
48. Green-Sadan T., Kinor N., Roth-Deri I., Geffen-Aricha R., Schindler C.J., and Yadid G. Transplantation of glial cell line-derived neurotrophic factor-expressing cells into the striatum and nucleus accumbens attenuates acquisition of cocaine self-administration in rats. Eur J Neurosci 18 (2003) 2093-2098
49. Green-Sadan T., Kuttner Y., Lublin-Tennenbaum T., Kinor N., Boguslavsky Y., Margel S., et al. Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of cocaine self-administration in rats. Exp Neurol 194 (2005) 97-105
50. Griffin III W.C., Boger H.A., Granholm A.C., and Middaugh L.D. Partial deletion of glial cell line-derived neurotrophic factor (GDNF) in mice: effects on sucrose reward and striatal GDNF concentrations. Brain Res 1068 (2006) 257-260
51. Harding A.S., and Hancock J.F. Using plasma membrane nanoclusters to build better signaling circuits. Trends Cell Biol 18 (2008) 364-371
52. Hayashi H., Ichihara M., Iwashita T., Murakami H., Shimono Y., Kawai K., et al. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19 (2000) 4469-4475
53. He D.Y., McGough N.N., Ravindranathan A., Jeanblanc J., Logrip M.L., Phamluong K., et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 25 (2005) 619-628
54. He D.Y., and Ron D. Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, Ibogaine. FASEB J 20 (2006) 2420-2422
55. He D.Y., and Ron D. Glial cell line-derived neurotrophic factor reverses ethanol-mediated increases in tyrosine hydroxylase immunoreactivity via altering the activity of heat shock protein 90. J Biol Chem 283 (2008) 12811-12818
56. Hebert M.A., Van Horne C.G., Hoffer B.J., and Gerhardt G.A. Functional effects of GDNF in normal rat striatum: presynaptic studies using in vivo electrochemistry and microdialysis. J Pharmacol Exp Ther 279 (1996) 1181-1190
57. Hou J.G., Lin L.F., and Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem 66 (1996) 74-82
58. Hudson J., Granholm A.C., Gerhardt G.A., Henry M.A., Hoffman A., Biddle P., et al. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36 (1995) 425-432
59. Hyman S.E., Malenka R.C., and Nestler E.J. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29 (2006) 565-598
60. Jain S., Golden J.P., Wozniak D., Pehek E., Johnson Jr. E.M., and Milbrandt J. RET is dispensable for maintenance of midbrain dopaminergic neurons in adult mice. J Neurosci 26 (2006) 11230-11238
61. Jankovic J., and Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 21 (2007) 677-692
62. Jeanblanc J., He D.Y., McGough N.N., Logrip M.L., Phamluong K., Janak P.H., and Ron D. The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption. J Neurosci 24 (2006) 10542-10552
63. Jing S., Wen D., Yu Y., Holst P.L., Luo Y., Fang M., et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85 (1996) 1113-1124
64. Jongen J.L., Haasdijk E.D., Sabel-Goedknegt H., van der Burg J., Vecht Ch J., and Holstege J.C. Intrathecal injection of GDNF and BDNF induces immediate early gene expression in rat spinal dorsal horn. Exp Neurol 194 (2005) 255-266
65. Kaminska B., Gaweda-Walerych K., and Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants-facts and hypotheses. J Cell Mol Med 8 (2004) 45-58
66. Kastin A.J., Akerstrom V., and Pan W. Glial cell line-derived neurotrophic factor does not enter normal mouse brain. Neurosci Lett 340 (2003) 239-241
67. Kilic U., Kilic E., Dietz G.P., and Bahr M. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke 34 (2003) 1304-1310
68. Kinoshita T., Fujita M., and Maeda Y. Biosynthesis, remodelling and functions of mammalian GPI-anchored proteins: recent progress. J Biochem 144 (2008) 287-294
69. Kirik D., Georgievska B., and Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 7 (2004) 105-110
70. Kobori N., Waymire J.C., Haycock J.W., Clifton G.L., and Dash P.K. Enhancement of tyrosine hydroxylase phosphorylation and activity by glial cell line-derived neurotrophic factor. J Biol Chem 279 (2004) 2182-2191
71. Koob G.F., Sanna P.P., and Bloom F.E. Neuroscience of addiction. Neuron 21 (1998) 467-476
72. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
73. Lapchak P.A., Jiao S., Collins F., and Miller P.J. Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection. Brain Res 747 (1997) 92-102
74. Ledda F., Bieraugel O., Fard S.S., Vilar M., and Paratcha G. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 28 (2008) 39-49
75. Ledda F., Paratcha G., Sandoval-Guzman T., and Ibanez C.F. GDNF and GFRalpha1 promote formation of neuronal synapses by ligand-induced cell adhesion. Nat Neurosci 10 (2007) 293-300
76. Levitt M., Spector S., Sjoerdsma A., and Udenfriend S. Elucidation of the rate-limiting step in norepinephrine biosynthesis in the perfused guinea-pig heart. J Pharmacol Exp Ther 148 (1965) 1-8
77. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons [see comments]. Science 260 (1993) 1130-1132
78. Lu L., Dempsey J., Liu S.Y., Bossert J.M., and Shaham Y. A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal. J Neurosci 24 (2004) 1604-1611
79. Maas U., and Strubelt S. Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction. Med Hypotheses 67 (2006) 960-964
80. Maciulaitis R., Kontrimaviciute V., Bressolle F.M., and Briedis V. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol 27 (2008) 181-194
81. Maisonneuve I.M., and Glick S.D. Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. Pharmacol Biochem Behav 75 (2003) 607-618
82. Maruyama W., Nitta A., Shamoto-Nagai M., Hirata Y., Akao Y., Yodim M., et al. N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 44 (2004) 393-400
83. Mash D.C., Kovera C.A., Buck B.E., Norenberg M.D., Shapshak P., Hearn W.L., et al. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci 844 (1998) 274-292
84. Matsuo A., Nakamura S., and Akiguchi I. Immunohistochemical localization of glial cell line-derived neurotrophic factor family receptor alpha-1 in the rat brain: confirmation of expression in various neuronal systems. Brain Res 859 (2000) 57-71
85. McGough N.N., He D.Y., Logrip M.L., Jeanblanc J., Phamluong K., Luong K., Kharazia V., Janak P.H., and Ron D. RACK1 and brain-derived neurotrophic factor: a homeostatic pathway that regulates alcohol addiction. J Neurosci 24 (2004) 10542-10552
86. Messer C.J., Eisch A.J., Carlezon Jr. W.A., Whisler K., Shen L., Wolf D.H., et al. Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. Neuron 26 (2000) 247-257
87. Millan M.J., Maiofiss L., Cussac D., Audinot V., Boutin J.A., and Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303 (2002) 791-804
88. Moore M.W., Klein R.D., Farinas I., Sauer H., Armanini M., Phillips H., et al. Renal and neuronal abnormalities in mice lacking GDNF. Nature 382 (1996) 76-79
89. Nagatsu T., Levitt M., and Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 239 (1964) 2910-2917
90. Naveilhan P., Neveu I., Wion D., and Brachet P. 1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport 7 (1996) 2171-2175
91. Newman-Tancredi A., Cussac D., Audinot V., Nicolas J.P., De Ceuninck F., Boutin J.A., and Millan M.J. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 303 (2002) 805-814
92. Newman-Tancredi A., Cussac D., Quentric Y., Touzard M., Verriele L., Carpentier, N., and Millan M.J. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303 (2002) 815-822
93. Newton P.M., and Ron D. Protein kinase C and alcohol addiction. Pharmacol Res 55 (2007) 570-577
94. Nitta A., Nishioka H., Fukumitsu H., Furukawa Y., Sugiura H., Shen L., et al. Hydrophobic dipeptide Leu-Ile protects against neuronal death by inducing brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis. J Neurosci Res 78 (2004) 250-258
95. Niwa M., Nitta A., Shen L., Noda Y., and Nabeshima T. Involvement of glial cell line-derived neurotrophic factor in inhibitory effects of a hydrophobic dipeptide Leu-Ile on morphine-induced sensitization and rewarding effects. Behav Brain Res 179 (2007) 167-171
96. Niwa M., Nitta A., Yamada Y., Nakajima A., Saito K., Seishima M., et al. Tumor necrosis factor-alpha and its inducer inhibit morphine-induced rewarding effects and sensitization. Biol Psychiatry 62 (2007) 658-668
97. Niwa M., Nitta A., Yamada Y., Nakajima A., Saito K., Seishima M., et al. An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization. Biol Psychiatry 61 (2007) 890-901
98. Nosrat C.A., Tomac A., Lindqvist E., Lindskog S., Humpel C., Stromberg I., et al. Cellular expression of GDNF mRNA suggests multiple functions inside and outside the nervous system. Cell Tissue Res 286 (1996) 191-207
99. O'Hearn E., and Molliver M.E. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 55 (1993) 303-310
100. Ohta K., Fujinami A., Kuno S., Sakakimoto A., Matsui H., Kawahara Y., et al. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 71 (2004) 162-168
101. Ohta K., Kuno S., Mizuta I., Fujinami A., Matsui H., and Ohta M. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Life Sci 73 (2003) 617-626
102. Ortiz J., DeCaprio J.L., Kosten T.A., and Nestler E.J. Strain-selective effects of corticosterone on locomotor sensitization to cocaine and on levels of tyrosine hydroxylase and glucocorticoid receptor in the ventral tegmental area. Neuroscience 67 (1995) 383-397
103. Ortiz J., Fitzgerald L.W., Lane S., Terwilliger R., and Nestler E.J. Biochemical adaptations in the mesolimbic dopamine system in response to repeated stress. Neuropsychopharmacology 14 (1996) 443-452
104. Papoutian A., and Reichardt L.F. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 11 (2001) 272-280
105. Paratcha G., Ledda F., Baars L., Coulpier M., Besset V., Anders J., et al. Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts. Neuron 29 (2001) 171-184
106. Paratcha G., Ledda F., and Ibanez C.F. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 113 (2003) 867-879
107. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gomez-Diaz R., and Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11 (2008) 755-761
108. Pichel J.G., Shen L., Sheng H.Z., Granholm A.C., Drago J., Grinberg A., et al. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382 (1996) 73-76
109. Pierchala B.A., Milbrandt J., and Johnson Jr. E.M. Glial cell line-derived neurotrophic factor-dependent recruitment of Ret into lipid rafts enhances signaling by partitioning Ret from proteasome-dependent degradation. J Neurosci 26 (2006) 2777-2787
110. Pochon N.A., Menoud A., Tseng J.L., Zurn A.D., and Aebischer P. Neuronal GDNF expression in the adult rat nervous system identified by in situ hybridization. Eur J Neurosci 9 (1997) 463-471
111. Popik P., Layer R.T., and Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol Rev 47 (1995) 235-253
112. Rezvani A.H., Overstreet D.H., Yang Y., Maisonneuve I.M., Bandarage U.K., Kuehne M.E., et al. Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol Biochem Behav 58 (1997) 615-619
113. Rosenblad C., Georgievska B., and Kirik D. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci 17 (2003) 260-270
114. Russo S.J., Bolanos C.A., Theobald D.E., DeCarolis N.A., Renthal W., Kumar A., et al. IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. Nat Neurosci 10 (2007) 93-99
115. Sajadi A., Bauer M., Thony B., and Aebischer P. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production. J Neurochem 93 (2005) 1482-1486
116. Sakai A., Asada M., Seno N., and Suzuki H. Involvement of neural cell adhesion molecule signaling in glial cell line-derived neurotrophic factor-induced analgesia in a rat model of neuropathic pain. Pain 137 (2008) 378-388
117. Sanchez B., Lopez-Martin E., Segura C., Labandeira-Garcia J.L., and Perez-Fernandez R. 1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. Brain Res Mol Brain Res 108 (2002) 143-146
118. Sanchez M.P., Silos-Santiago I., Frisen J., He B., Lira S.A., and Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382 (1996) 70-73
119. Sarabi A., Hoffer B.J., Olson L., and Morales M. GFRalpha-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area. J Comp Neurol 441 (2001) 106-117
120. Schaar D.G., Sieber B.A., Dreyfus C.F., and Black I.B. Regional and cell-specific expression of GDNF in rat brain. Exp Neurol 124 (1993) 368-371
121. Self D.W., McClenahan A.W., Beitner-Johnson D., Terwilliger R.Z., and Nestler E.J. Biochemical adaptations in the mesolimbic dopamine system in response to heroin self-administration. Synapse 21 (1995) 312-318
122. Semba J., Akanuma N., Wakuta M., Tanaka N., and Suhara T. Alterations in the expressions of mRNA for GDNF and its receptors in the ventral midbrain of rats exposed to subchronic phencyclidine. Brain Res Mol Brain Res 124 (2004) 88-95
123. Shoptaw S., Watson D.W., Reiber C., Rawson R.A., Montgomery M.A., Majewska M.D., et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 100 Suppl 1 (2005) 78-90
124. Springer J.E., Mu X., Bergmann L.W., and Trojanowski J.Q. Expression of GDNF mRNA in rat and human nervous tissue. Exp Neurol 127 (1994) 167-170
125. Stromberg I., Bjorklund L., Johansson M., Tomac A., Collins F., Olson L., et al. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol 124 (1993) 401-412
126. Suzuki C., Murakumo Y., Kawase Y., Sato T., Morinaga T., Fukuda N., et al. A novel GDNF-inducible gene, BMZF3, encodes a transcriptional repressor associated with KAP-1. Biochem Biophys Res Commun 366 (2008) 226-232
127. Sweatt J.D. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 76 (2001) 1-10
128. Tang M.J., Worley D., Sanicola M., and Dressler G.R. The RET-glial cell-derived neurotrophic factor (GDNF) pathway stimulates migration and chemoattraction of epithelial cells. J Cell Biol 142 (1998) 1337-1345
129. Tansey M.G., Baloh R.H., Milbrandt J., and Johnson Jr. E.M. GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival. Neuron 25 (2000) 611-623
130. Tokugawa K., Yamamoto K., Nishiguchi M., Sekine T., Sakai M., Ueki T., et al. XIB4035, a novel nonpeptidyl small molecule agonist for GFRalpha-1. Neurochem Int 42 (2003) 81-86
131. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 (1995) 335-339
132. Tomac A., Widenfalk J., Lin L.F., Kohno T., Ebendal T., Hoffer B.J., et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci U S A 92 (1995) 8274-8278
133. Treanor J.J., Goodman L., de Sauvage F., Stone D.M., Poulsen K.T., Beck C.D., et al. Characterization of a multicomponent receptor for GDNF. Nature 382 (1996) 80-83
134. Trupp M., Arenas E., Fainzilber M., Nilsson A.S., Sieber B.A., Grigoriou M., et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381 (1996) 785-789
135. Trupp M., Belluardo N., Funakoshi H., and Ibanez C.F. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. J Neurosci 17 (1997) 3554-3567
136. Trupp M., Scott R., Whittemore S.R., and Ibanez C.F. Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J Biol Chem 274 (1999) 20885-20894
137. Tsui-Pierchala B.A., Ahrens R.C., Crowder R.J., Milbrandt J., and Johnson Jr. E.M. The long and short isoforms of ret function as independent signaling complexes. J Biol Chem 277 (2002) 34618-34625
138. Tsui-Pierchala B.A., Encinas M., Milbrandt J., and Johnson Jr. E.M. Lipid rafts in neuronal signaling and function. Trends Neurosci 25 (2002) 412-417
139. Verity A.N., Wyatt T.L., Lee W., Hajos B., Baecker P.A., Eglen R.M., et al. Differential regulation of glial cell line-derived neurotrophic factor (GDNF) expression in human neuroblastoma and glioblastoma cell lines. J Neurosci Res 55 (1999) 187-197
140. Visanji N.P., Orsi A., Johnston T.H., Howson P.A., Dixon K., Callizot N., et al. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 22 (2008) 2488-2497
141. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M., and Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 64 (2007) 1575-1579
142. Wang C.Y., Yang F., He X., Chow A., Du J., Russell J.T., et al. Ca(2+) binding protein frequenin mediates GDNF-induced potentiation of Ca(2+) channels and transmitter release. Neuron 32 (2001) 99-112
143. Wang H.J., Cao J.P., Yu J.K., Zhang L.C., Jiang Z.J., and Gao D.S. Calbindin-D28K expression induced by glial cell line-derived neurotrophic factor in substantia nigra neurons dependent on PI3K/Akt/NF-kappaB signaling pathway. Eur J Pharmacol 595 (2008) 7-12
144. Wang J., Chen G., Lu B., and Wu C.P. GDNF acutely potentiates Ca2+ channels and excitatory synaptic transmission in midbrain dopaminergic neurons. Neurosignals 12 (2003) 78-88
145. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., and Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331 (1994) 904-909
146. Weinreb O., Amit T., Bar-Am O., and Youdim M.B. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci 1122 (2007) 155-168
147. Yan Y., Yamada K., Niwa M., Nagai T., Nitta A., and Nabeshima T. Enduring vulnerability to reinstatement of methamphetamine-seeking behavior in glial-cell-line-derived neurotrophic factor mutant mice. Faseb J 21 (2007) 1994-2004
148. Yang F., Feng L., Zheng F., Johnson S.W., Du J., Shen L., et al. GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons. Nat Neurosci 4 (2001) 1071-1078
149. Youdim M.B.H., and Van der Schyf C. Magic bullets or novel multimodal drugs with various CNS targets for Parkinson's disease?. Nature Rev Drug Discov (2007) doi:10.1038/nrd2330
150. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., and Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 (2007) 39-46
151. Zhang Y., Xia Z., Hu Y., Orsi A., and Rees D. Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+. FEBS Lett 582 (2008) 956-960